[HTML][HTML] Evolving acquired vemurafenib resistance in a BRAF V600E mutant melanoma PDTX model to reveal new potential targets
J Tóvári, D Vári-Mező, SE Surguta, A Ladányi, A Kigyós… - Cells, 2023 - mdpi.com
Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets
J Tóvári, D Vári-Mező, ES Sára, A Ladányi, A Kigyós… - Cells, 2023 - search.proquest.com
Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets
J Tóvári, D Vári-Mező, SE Surguta, A Ladányi… - Cells, 2023 - pubmed.ncbi.nlm.nih.gov
Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets.
J Tóvári, D Vári-Mező, SE Surguta, A Ladányi, A Kigyós… - Cells, 2023 - europepmc.org
Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
[HTML][HTML] Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets
J Tóvári, D Vári-Mező, SE Surguta, A Ladányi, A Kigyós… - Cells, 2023 - ncbi.nlm.nih.gov
Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets.
J Tóvári, D Vári-Mező, SE Surguta… - Cells (2073 …, 2023 - search.ebscohost.com
Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …
strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but …